You are here

IBA SA : TRANSPARENCY NOTIFICATION

IBA - TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, January 12, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 12, 2018.

Reason for the notification Upwards crossing of the 3% threshold further to the acquisition of shares -and thus voting rights- held as loan collateral
Persons subject to the notification requirement IBA SA, issuer
Persons that dispose of voting rights Kempen Capital Management NV
Transaction date   01/01/2018
Threshold that is crossed (in %)   3%
Upwards crossing further to the acquisition of voting rights
Denominator   29 962 246
Voting rights (number)   900 174
Voting rights (%)   3,00%
Chain of control Van Lanschot Kempen N.V. < 100%> F. van Lanschot Banklers NV <100%> kempen & Co NV <100%> Kempen Capital Management NV. Kempen se réfère à la declaration d'indépendance (datée du 15 novembre 2017).
Additional information Kempen Capital Management NV appeals for Art. 11 of the (Transparency) Law (May 2, 2007), by which an exemption is acquired.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Stephanie Bauwin
Legal Counsel
+32 10 203 924
Stephanie.bauwin@iba-group.com

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/db35d873-23c8-457d-8a08-06c30d34761d

Friday, January 12, 2018 - 12:01

More Headlines

Some see the loss of an important, unbiased source of information.
Insurers are proceeding cautiously, but the large insurers are speeding up their approvals.
The move is considered part of the antiterrorism effort.
An impurity has been found to be carcinogenic.
But diabetes group tamp down expectations.
Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
A meta-analysis that included 18 million participants found no protection from heart disease or stroke.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.